Platelet dysfunction after normothermic cardiopulmonary bypass in children: Effect of high-dose aprotinin

Thrombosis and Haemostasis

Volumn 98, Issue 2, 2007, Pages 385-391

  Flaujac, Claire ^a   Pouard, Philippe ^a   Boutouyrie, Pierre ^b   Emmerich, Joseph ^c   Bachelot Loza, Christilla ^c   Lasne, Dominique ^a,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Aprotinin; Cardiopulmonary bypass; Pediatric cardiac surgery; Platelet

Indexed keywords

ADRENALIN; APROTININ; HEPARIN; MILRINONE; PADGEM PROTEIN; PROTAMINE; PROTHROMBIN;

ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CARDIOPULMONARY BYPASS; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; INFANT; LOW DRUG DOSE; MALE; NEWBORN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION;

EID: 34547881091     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-12-0723     Document Type: Article

References (27)

1. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-834.
2. Rinder CS, Gaal D, Student LA, et al. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 107: 280-288.
3. Hezard N, Potron G, Schlegel N, et al. Unexpected persistence of platelet hyporeactivity beyond the neonatal period: a flow cytometric study in neonates, infants and older children. Thromb Haemost 2003; 90: 116-123.
4. Ichinose F, Uezono S, Muto F, et al. Platelet hypo-reactivity in young infants during cardiopulmonary by-pass. Anesth Analg 1999; 88: 258-262.
5. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-1947.
6. Huang H, Ding W, Su Z, et al. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993; 106: 11-18.
7. Poullis M, Manning R, Laffan M, et al. The anti-thrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg 2000; 120: 370-378.
8. Kozek-Langenecker SA, Mohammad SF, Masaki T, et al. The effects of aprotonin on platelets in vitro using whole blood flow cytometry. Anesth Analg 2000; 90: 12-16.
9. Bradfield JF, Bode AP. Aprotinin restores the adhesive capacity of dysfunctional platelets. Thromb Res 2003; 109: 181-188.
10. Day JR, Punjabi PP, Randi AM, et al. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004; 110: 2597-2600.
11. Poullis M, Landis RC, Taylor KM. Aprotinin: is it prothrombotic? Perfusion 2001; 16: 401-409.
12. Wildevuur CR, Eijsman L, Roozendaal KJ, et al. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989; 3: 533-537; discussion 537-538.
13. Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003; 75: 430-437.
14. Speziale G, Ferroni P, Ruvolo G, et al. Effect of normothermic versus hypothermic cardiopulmonary bypass on cytokine production and platelet function. J Cardiovasc Surg (Torino) 2000; 41: 819-827.
15. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992; 6: 76-100.
16. Khairy M, Lasne D, Brohard-Bohn B, et al. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 2001; 85: 1090-1096.
17. Guay J, Ruest P, Lortie L. Cardiopulmonary by-pass induces significant platelet activation in children undergoing open-heart surgery. Eur J Anaesthesiol 2004; 21: 953-956.
18. Nurden A, Cazes E, Bihour C, et al. Confirmation that GP Ib-IX complexes have a reduced surface distribution on platelets activated by thrombin and TRAP-14-mer peptide. Br J Haematol 1995; 90: 645-654.
19. van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-796; discussion 796-797.
20. Boldt J, Knothe C, Zickmann B, et al. Platelet function in cardiac surgery: influence of temperature and aprotinin. Ann Thorac Surg 1993; 55: 652-658.
21. Jonas RA, Wypij D, Roth SJ, et al. The influence of hemodilution on outcome after hypothermic cardio-pulmonary bypass: results of a randomized trial in infants. J Thorac Cardiovasc Surg 2003; 126: 1765-1774.
22. D'Errico CC, Munro HM, Bove EL. Pro: the routine use of aprotinin during pediatric cardiac surgery is a benefit. J Cardiothorac Vasc Anesth 1999; 13: 782-784.
23. Williams GD, Ramamoorthy C. Con: the routine use of aprotinin during pediatric cardiac surgery is not a benefit. J Cardiothorac Vasc Anesth 1999; 13: 785-788.
24. Arnold DM, Fergusson DA, Chan AK, et al. Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth Analg 2006; 102: 731-737.
25. Costello JM, Backer CL, de Hoyos A, et al. Aprotinin reduces operative closure time and blood product use after pediatric bypass. Ann Thorac Surg 2003; 75: 1261-1266.
26. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-365.
27. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46: 327-338.